Crimean-Congo hemorrhagic fever virus vaccine

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9474796
APP PUB NO 20140050761A1
SERIAL NO

13829105

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICESOFFICE OF TECHNOLOGY TRANSFER NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE SUITE 700 MSC 7788 BETHESDA MD 20892-7788

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bergeron, Eric Atlanta, US 12 240
Deaton, Michelle Kay Denver, US 2 2
Nichol, Stuart T Atlanta, US 16 43
Pegan, Scott Dusan Denver, US 3 6

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 25, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00